Elys A. Green, Steven P. Garrick, Briana Peterson, Philip J. Berger, Robert Galinsky, Rod W. Hunt, Steven X. Cho, Jane E. Bourke, Marcel F. Nold, Claudia A. Nold-Petry
Hudson Institute of Medical Research. Monash University. Monash Children’s Hospital.
Australia
International Journal of Molecular Sciences
Int J Mol Sci 2023; 24:
DOI: 10.3390/ijms24032795
Abstract
Preterm birth is a major contributor to neonatal morbidity and mortality. Complications of prematurity such as bronchopulmonary dysplasia (BPD, affecting the lung), pulmonary hypertension associated with BPD (BPD-PH, heart), white matter injury (WMI, brain), retinopathy of prematurity (ROP, eyes), necrotizing enterocolitis (NEC, gut) and sepsis are among the major causes of long-term morbidity in infants born prematurely. Though the origins are multifactorial, inflammation and in particular the imbalance of pro- and anti-inflammatory mediators is now recognized as a key driver of the pathophysiology underlying these illnesses. Here, we review the involvement of the interleukin (IL)-1 family in perinatal inflammation and its clinical implications, with a focus on the potential of these cytokines as therapeutic targets for the development of safe and effective treatments for early life inflammatory diseases.
Category
Class III. Pulmonary Hypertension Associated with Lung Disease
Class I. Pulmonary Hypertension Associated with Inflammation
Acquired Patient Factors Associated with Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Filed (PHiled). Greater than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes